Ixazomib Frontline Triplet Misses PFS Endpoint in Transplant-Ineligible Myeloma
March 10th 2020
The triplet therapy of ixazomib, lenalidomide, and dexamethasone showed an improvement in progression-free survival, but it was not statistically significant, compared with lenalidomide/dexamethasone alone for patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplant.